scholarly journals In Silico Feasibility Study of Carbon Ion Radiotherapy With Simultaneous Integrated Boost for Head and Neck Adenoid Cystic Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Edoardo Mastella ◽  
Silvia Molinelli ◽  
Giuseppe Magro ◽  
Stefania Russo ◽  
Maria Bonora ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Simultaneous Integrated Boost ◽  
Carbon Ion Radiotherapy ◽  
Dose Distributions ◽  
Carbon Ion ◽  
Adenoid Cystic ◽  
Sequential Boost ◽  
Integrated Boost ◽  
Dose Levels

PurposeIn carbon ion radiotherapy (CIRT), a simultaneous integrated boost (SIB) approach has not been fully exploited so far. The feasibility of a CIRT-SIB strategy for head and neck adenoid cystic carcinoma (ACC) patients was investigated in order to improve treatment planning dose distributions.Methods and MaterialsCIRT plans of 10 ACC patients treated at the National Center for Oncological Hadrontherapy (CNAO, Pavia, Italy) with sequential boost (SEQ) irradiation and prescription doses of 41.0 Gy [relative biological effectiveness (RBE)]/10 fractions to low-risk (LR) clinical target volume (CTV) plus 24.6 Gy(RBE)/6 fractions to the high-risk (HR) CTV were re-planned with two SIB dose levels to the LR-CTV, namely, 48.0 Gy(RBE) and 54.4 Gy(RBE). While planning with SIB, the HR-CTV coverage had higher priority, with fixed organ-at-risk dose constraints among the SIB and SEQ plans. The homogeneity and conformity indexes were selected for CTV coverage comparison. The biologically effective dose (BED) was calculated to compare the different fractionation schemes.ResultsComparable HR-CTV coverage was achieved with the treatment approaches, while superior conformality and homogeneity were obtained with the SIB technique in both CTVs. With the SEQ, SIB48.0, and SIB54.4, the LR-CTV median doses were respectively 50.3%, 11.9%, and 6.0% higher than the prescriptions. Significant reductions of the median and near-maximum BEDs were achieved with both SIB dose levels in the LR-CTV.ConclusionsThe SIB approach resulted in highly conformal dose distributions with the reduction of the unintended dose to the LR-CTV. A prescription dose range for the LR-CTV will be clinically defined to offer tailored personalized treatments, according to the clinical and imaging characteristics of the patients.

scholarly journals EP-1189 Adenoid Cystic Carcinoma Of The Head And Neck Treated With Carbon Ion Radiotherapy At CNAO

2019 ◽  
Vol 133 ◽  
pp. S659
Author(s):  
M. Bonora ◽  
B. Vischioni ◽  
D. Caivano ◽  
A. Hasegawa ◽  
V. Vitolo ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
Adenoid Cystic

Carbon Ion Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck

2011 ◽  
Vol 81 (2) ◽  
pp. S77-S78
Author(s):  
A. Hasegawa ◽  
M. Koto ◽  
R. Takagi ◽  
T. Morikawa ◽  
T. Kamada ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
Adenoid Cystic

OC-0377: Carbon ion radiotherapy for adenoid cystic carcinoma of the head and neck

2014 ◽  
Vol 111 ◽  
pp. S145-S146
Author(s):  
A. Hasegawa ◽  
M. Koto ◽  
R. Takagi ◽  
H. Ikawa ◽  
H. Tsuji ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
Adenoid Cystic

scholarly journals Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kristin Lang ◽  
Sebastian Adeberg ◽  
Semi Harrabi ◽  
Thomas Held ◽  
Meinhard Kieser ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Local Control ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ions ◽  
Node Negative ◽  
Carbon Ion ◽  
Adenoid Cystic ◽  
High Let

Abstract Background Adenoid cystic carcinoma is a rare form of head and neck cancer with a slow, but aggressive growth pattern which remains a challenge for local tumor control. Based on phase II data, radiation treatment using partially high LET radiation results in a prolonged PFS and OS. There is a paucity of randomized clinical data examining the role of the use of high LET radiation only. Therefore, the purpose of this prospective clinical trial is to analyze local control rates in patients with node negative ACC treated with carbon ion radiotherapy alone compared to a combined modality approach. Methods This trial is conducted as a prospective, open-label, phase II, two-armed, investigator-initiated study comparing the local control rates in node negative ACCs of the head and neck treated either with sole carbon ion radiotherapy or a combination of carbon ions and photons. Secondary outcomes investigated are progression-free survival, overall survival, acute and late toxicity, and quality of life. A total of 314 patients will be randomly assigned to C12 treatment alone or bimodal treatment: Patients in the experimental group will receive a dose of 51 Gy (RBE) in 17 fractions and a boost of 15 Gy (RBE) in 5 fractions. Patients in the control group will receive 25 fractions photon IMRT 50Gy and a boost using 8 × 3 Gy (RBE) carbon ions. Local control will be assessed in regular follow up examinations until 5 years after the completion of treatment. Discussion The present trial aims to evaluate local control rates to compare sole carbon ion radiotherapy to bimodal radiotherapy with carbon ions and photons in patients with node negative ACCs of the head and neck region. Local control is selected as the primary endpoint due to its major clinical relevance because of slow but aggressive growth patterns. Trial registration The study was prospectively registered on 2nd January 2020: ClinicalTrials.gov, NCT04214366. “Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation (ACCO)”. Study status Under recruitment, participant recruitment is not completed. Start of recruitment was January 2020. There are no results been published or submitted to any journal.

scholarly journals PO-0722 Carbon ion radiotherapy for adenoid cystic carcinoma in the head-and-neck

2019 ◽  
Vol 133 ◽  
pp. S370-S371
Author(s):  
A. Hasegawa ◽  
B. Vischioni ◽  
M. Bonora ◽  
S. Ronchi ◽  
S. Molinelli ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
Adenoid Cystic

scholarly journals Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jian Chen ◽  
Jingfang Mao ◽  
Ningyi Ma ◽  
Kai-Liang Wu ◽  
Jiade Lu ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Group Performance ◽  
Primary Tumour ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Tumour Response ◽  
Carbon Ion Radiotherapy ◽  
Rare Tumour ◽  
Carbon Ion ◽  
Adenoid Cystic

Abstract Background Tracheobronchial adenoid cystic carcinoma (TACC) is a rare tumour. About one-third of patients miss their chance of surgery or complete resection as it is mostly detected in the advanced stage; hence, photon radiotherapy (RT) is used. However, the outcomes of photon RT remain unsatisfactory. Carbon ion radiotherapy (CIRT) is thought to improve the therapeutic gain ratio; however, the outcomes of CIRT in TACC are unclear. Therefore, we aimed to assess the effects and toxicities of CIRT in patients with TACC. Methods The inclusion criteria were as follows: 1) age 18–80 years; 2) Eastern Cooperative Oncology Group Performance Status 0–2; 3) histologically confirmed TACC; 4) stage III–IV disease; 5) visible primary tumour; and 6) no previous RT history. The planned prescription doses of CIRT were 66–72.6 GyE/22–23 fractions. The rates of overall survival (OS), local control (LC), and progression-free survival (PFS) were calculated using the Kaplan-Meier method. Treatment-induced toxicities and tumour response were scored according to the Common Terminology Criteria for Adverse Events and Response Evaluation Criteria in Solid Tumors, respectively. Results Eighteen patients with a median age of 48 (range 30–73) years were enrolled. The median follow-up time was 20.7 (range 5.8–44.1) months. The overall response rate was 88.2%. Five patients developed lung metastasis after 12.2–41.0 months and one of them experienced local recurrence at 31.9 months after CIRT. The rates of 2-year OS, LC, and PFS were 100, 100, and 61.4%, respectively. Except for one patient who experienced grade 4 tracheal stenosis, which was relieved after stent implantation, no other ≥3 grade toxicities were observed. Conclusions CIRT might be safe and effective in the management of TACC based on a short observation period. Further studies with more cases and longer observation are warranted.

Evaluation of the safety and efficacy of carbon ion radiotherapy for locally advanced adenoid cystic carcinoma of the tongue base

Head & Neck ◽  
2016 ◽  
Vol 38 (S1) ◽  
pp. E2122-E2126 ◽  
Author(s):  
Masashi Koto ◽  
Azusa Hasegawa ◽  
Ryo Takagi ◽  
Hiroaki Ikawa ◽  
Kensuke Naganawa ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Locally Advanced ◽  
Tongue Base ◽  
Carbon Ion Radiotherapy ◽  
Safety And Efficacy ◽  
Carbon Ion ◽  
Adenoid Cystic ◽  
Carcinoma Of The Tongue
Sign in / Sign up

Export Citation Format

Share Document